Ipsen Inc Drug Patent Portfolio

Ipsen Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Ipsen Inc News

Ipsen finalizes the purchase of ImCheck Therapeutics, enhancing its oncology portfolio.

16 Dec, 2025

Crinetics Gains FDA Approval for Uncommon Hormonal Disorder, Positioning It to Compete with Major Medications From...

26 Sep, 2025

Ipsen's LANTIC Phase II trial in aesthetics introduces a unique, long-lasting treatment option.

23 Sep, 2025

FDA rejects Ipsen's request regarding popular drug Somatuline - Endpoints News

24 May, 2024

See More